Curiox Biosystems Co., Ltd (KOSDAQ: 445680)
South Korea
· Delayed Price · Currency is KRW 18,520
-190 (-1.02%)
Dec 20, 2024, 9:00 AM KST
Curiox Biosystems Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -12,372 | -10,040 | -11,495 | -14,524 | -6,279 |
| Depreciation & Amortization | 2,111 | 1,952 | 1,598 | 1,236 | 1,120 |
| Loss (Gain) From Sale of Assets | 6.44 | -13.02 | 12.11 | - | - |
| Asset Writedown & Restructuring Costs | - | - | - | 84.1 | - |
| Stock-Based Compensation | 498.96 | -8.84 | 678.35 | 613.76 | 167.82 |
| Provision & Write-off of Bad Debts | 25.46 | 17.29 | 1.88 | 12.66 | 27.41 |
| Other Operating Activities | 1,035 | -334.89 | 301.64 | 7,214 | 3,307 |
| Change in Accounts Receivable | -754.73 | 227.68 | 1,212 | 75.22 | -2,227 |
| Change in Inventory | 69.09 | 195.89 | -829.5 | -1,163 | 137.56 |
| Change in Accounts Payable | 90.17 | -688.69 | -1,509 | 809.8 | 1,192 |
| Change in Other Net Operating Assets | -868.85 | 528.91 | 140.75 | 516.07 | -106.52 |
| Operating Cash Flow | -10,159 | -8,164 | -9,888 | -5,126 | -2,661 |
| Capital Expenditures | -49.29 | -211.53 | -822.86 | -261.26 | -188.39 |
| Sale of Property, Plant & Equipment | 0 | 1.79 | - | - | 58.68 |
| Sale (Purchase) of Intangibles | - | - | -17.9 | - | - |
| Investment in Securities | - | 3,125 | 5,691 | -8,007 | 2,260 |
| Other Investing Activities | -8.21 | -16.69 | -116.92 | -43.25 | -26.19 |
| Investing Cash Flow | -57.5 | 2,898 | 4,734 | -8,311 | 2,105 |
| Long-Term Debt Issued | - | - | - | - | 131.79 |
| Long-Term Debt Repaid | - | -320.22 | -236.66 | -93.69 | -34.29 |
| Net Debt Issued (Repaid) | 19,627 | -320.22 | -236.66 | -93.69 | 97.51 |
| Issuance of Common Stock | 234.21 | 17,964 | - | - | - |
| Other Financing Activities | -27.68 | -0 | - | 13,087 | - |
| Financing Cash Flow | 19,833 | 17,644 | -236.66 | 16,999 | 97.51 |
| Foreign Exchange Rate Adjustments | 131.27 | -65.54 | -15.47 | 397.85 | -185.72 |
| Net Cash Flow | 9,748 | 12,312 | -5,407 | 3,960 | -644.51 |
| Free Cash Flow | -10,209 | -8,376 | -10,711 | -5,387 | -2,849 |
| Free Cash Flow Margin | -171.09% | -123.39% | -148.00% | -97.54% | -64.99% |
| Free Cash Flow Per Share | -636.16 | -586.28 | -1509.32 | -826.72 | -437.27 |
| Cash Interest Paid | 33.47 | 25.7 | 29.23 | 9.35 | 3.2 |
| Cash Income Tax Paid | 33.8 | 11.81 | 16.14 | -3.84 | 8.8 |
| Levered Free Cash Flow | 7,767 | -3,723 | -8,886 | -4,602 | - |
| Unlevered Free Cash Flow | 7,958 | -3,707 | -7,150 | -3,537 | - |
| Change in Net Working Capital | -13,141 | -1,278 | 1,448 | -85.32 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.